Activating Transcription Factor 3 regulates in part the enhanced tumour cell cytotoxicity of the histone deacetylase inhibitor M344 and cisplatin in combination

by St Germain Carly, O'Brien Anna, Dimitroulakos Jim
Published 2010-09-01

The effect of the histone deacetylase inhibitor M344 on BRCA1 expression in breast and ovarian cancer cells

by Niknejad Nima, O'Brien Anna M, Weberpals Johanne I, Garbuio Kyla D, Clark-Knowles Katherine V, Dimitroulakos Jim
Published 2011-08-01

The Role of Activating Transcription Factor 3 as a Regulator of DNA-Damaging Chemotherapy Cytotoxicity

by Hasim, Mohamed Shaad
Published 2019

Targeting the Mevalonate Pathway Enhances the Efficacy of Epidermal Growth Factor Receptor – Tyrosine Kinase Inhibitors in Head and Neck Squamous Cell Carcinoma

by Mukhtar, Lenah
Published 2020

ATF3 as a Key Regulator of Cisplatin Cytotoxicity: Combining ATF3 Inducing Agents Enhances Cisplatin Activity in NSCLC

by Baghai, Tabassom
Published 2018

Novel Combination Therapy: Monensin Potentiates Erlotinib-Induced Cytotoxicity

by Khalil, Dayekh
Published 2013

GGTI-298 in Combination with EGFR Inhibitors: Evaluating a Novel Therapy in Head and Neck Squamous Cell Carcinomas

by Zahr, Stephanie
Published 2013

Activating Transcription Factor 3 as a Regulator and Predictor of Cisplatin Response in Human Cancers

by O'Brien, Anna
Published 2012

The combination of pan-ErbB tyrosine kinase inhibitor CI-1033 and lovastatin: A potential novel therapeutic approach in squamous cell carcinoma of the head and neck

by Guimond, Tanya
Published 2011

Mechanism and Therapeutic Potential of Statin-Mediated Inhibition of Tyrosine Kinase Receptors

by Zhao, Tong Tong
Published 2011

The Role of Activating Transcription Factor 3 (ATF3) in Chemotherapeutic Induced Cytotoxicity

by St. Germain, Carly
Published 2011